At the most recent American Academy of Ophthalmology (AAO) Annual Meeting in Chicago, Texas Retina Associates’ , participated in a roundtable discussion with seven other retina specialists to share their real-world perspectives and clinical experiences with XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use. Approved by the U.S. Food and Drug Administration (FDA) in October 2021, it is a corticosteroid injection indicated for the treatment of associated with .
Macular edema is the accumulation of extracellular fluid in the macula, an area at the back of the eye. It is the most common sight-threatening complication of uveitis. Ocular corticosteroids are the primary treatment for macular edema associated with uveitis and are available in a variety of forms, including topical, injectable and implantable therapies. The suprachoroidal space is located between the sclera and choroid and goes all the way around the back part of the eye. An injection into this area is designed to deliver medication directly to the structures in the back of the eye.
Uveitis is a complex condition with many different causes. The faculty panel assembled for this patient case study series roundtable discussion shared their insights to help define the types of patients who most benefit from treatment with XIPERE. The 24-week PEACHTREE clinical trial and the 24-week MAGNOLIA extension study evaluated the drug’s efficacy and safety. Those two studies demonstrated that XIPERE delivers sustained visual and anatomic improvements in patients with macular edema associated with uveitis, with a low incidence of intraocular pressure elevation.